Better, local production, which I understand is neither quick nor easy.

I know nothing about the patent law, but according to the article, drug is patented. Assuming the process is not open-source, I'd argue that other countries would be looking for alternative vaccinations.

From the article:

The drug, which was trialed in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement.